PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of the Paperwork peduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Sheet 1

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/613,654	-		
Filing Date	07/03/2003			
First Named Inventor	Gad Keren			
Art Unit	3763			
Examiner Name	Mark K. Han			
Attorney Docket Number	FLO5360.01A1			

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials* No.1		Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
MFD		^{US-} 4,909,252	03-20-1990	Goldberger		
		^{US-} 5,167,628	12-01-1992	Boyles		
		^{US-} 5,226,888	07-13-1993	Arney		
		US- 5,257,974	11-02-1993	Cox		
		^{US-} 5,421,826	06-06-1995	Crocker et al.		
		^{US-} 5,476,453	12-19-1995	Mehta		
		^{US-} 5,599,306	02-04-1997	Klein et al.		
		^{US-} 5,713,860	02-03-1998	Kaplan et al.		
		^{US-} 5,720,735	02-24-1998	Dorros		
- J.		^{US-} 5,766,151	06-16-1998	Valley et al.		
		^{US-} 5,807,895	09-15-1998	Stratton et al.		
		^{US-} 5,968,013	10-19-1999	Smith et al.		
		^{US-} 5,928,132	07-27-1999	Leschinsky		
		^{US-} 6,068,629	05-30-2000	Haissaguerre et al.		
		us- 6,287,608	09-11-2001	Levin et al.		
		US- 6,733,474	05-11-2004	Kusleika		
, ,		^{US-} 2004/0064089	04-01-2004	Kesten et al.		
V		^{US-} 2002/0169413	11-14-2002	Keren et al.		
		US-				

	_		IGN PATENT DOCL	MENTS		
Examiner Initials*		Foreign Patent Document Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	ד
MFD		WO 97/11737	04-03-1997	Erbel		
V		GB 2 239 675 A	07-10-1991	Shiu		
						L
·						┡
	L					L
				ł.		1

Examiner	/Matthew DeSanto/	Date	
Signature	/Matthew DeSanto/	Considered	01/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03) Complete If Known Spestitute for form 1449A/PTO 10/613,654 **Application Number** INFORMATION DISCLOSURE July 3, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Keren et al. 3763 Art Unit (use as many sheets as necessary) **Examiner Name** Mark Han 022352-000310US

Sheet

			U.S. PATENT D	OCUMENTS+	
		Document Number			
Examiner Initials*	Cite No.	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MFD	1	3,481,331	10/1/1974	Wilder et al.	
	2	4,248,224	2/3/1981	Jones	·
	3	5,613,980	3/25/1997	Chauhan	
	4	6,165,120	12/1/2000	Schweich et al.	
\mathbf{V}^{-}	5	6,468,241	10/22/2002	Gelfand et al.	
-					
•					
					-

Attorney Docket Number

			FOREIGN PA	TENT DOCUM	ENTS	(
		For	eign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant	I
Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Τ6	
MFD	6	WO	01/083016	4/27/2001	Keren et al.		
	7	wo	01/41861	6/1/2001	Levin et al.		
	8	wo	01/97687	12/27/2001	Levin et al.		
7/	9	wo	01/97717	12/27/2001	Levin et al.		
V		•				·	

Examiner Signature	MFD	Date Considered	,

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. All the propriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. 60413295 v1

TRAD MANUBILITIES OF FORM 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/613,654 Filing Date July 3, 2003 First Named Inventor Keren et al. Art Unit 3763 Mark K. Han Examiner Name

Complete if Known

(use as many sheets as necessary)

022352-000310US Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
MFD	10	AGOSTONI et al. Sustained Benefit from Ultrafiltration in Moderate Congestive heart failure Cardiology 2001:96 183-189	
	11	GRUBERG et al. The prognostic implications of further renal deterioration within 48 h of interventionary etc. J AM Coll Cardiol 2000, 20(5):540-548	
	12	HALPENNY et al. The effects of fendolopam on fenal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs, EUR J Anatestheisol, 2000 Aug: 17(8); 491-8 Abstract	
	13	KINI et al. A protocol for Prevention of Radiographic contrast Nepropathy etc. Catherization and Cardiovascular Interventions 2002, 55:169-173	
	14	KINI et al. Managing the High-Risk Patient: Experience with Fenoldopam etc. Rev. Cardiovas Med 2001:2(suppl 1) S19-S25	
	15	MADYOON, Use of Fenoldopam to Prevent Radiocontrast Nephropathy etc. Catherization and Cardiovascular Interventions 2001, 53:341-345	
	16	MATHUR et al., The effects of fenoldopam, a selective dopamine receptor agonist, on renal hemodynamics etc. Abstract only. Crit Cre Med Sep 1999: 27(9) 1832-1837	
	17	MULLER et al. Prevention of Contrast Media Associated Nephropathy, Arch Intern Med, Feb 2002, Vol. 162 pp. 329-336	
	18	NOHRIA et al. Medical Management of Advanced Heart Failure, JAMA, Feb. 6 2002, Vol. 162, pp. 628-640	
	19	TUMLIN et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontracts dye infusion, AM heart J 2002; 894-903	
	20	UMRANI et al., Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats, Clin Exp Hypertens, 2002 Apr 24 (3): 207-19 Abstract only	
$\overline{\mathbf{V}}$	21	ZACHERL et al. Periaterial Papverine Applications Improves Intraoperative Kidney Function etc. Journal of Surgical Research 103:268-271 (2002)	

			
Examiner Signature	/Matthew DeSanto/	Date Considered	01/05/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE u.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known	
Application Number	10/613,654	
Filing Date	07/03/03	
First Named Inventor	KEREN, ET AL.	
Art Unit		
Examiner Name		
Attorney Docket Number	FLO5360.01A1	

			U. S. PATEN	TOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MFD		^{US-} 2,499,045	02/01/1950	F,R, WALKER ET AL,	
ı		^{US-} 3,455,298	07/1969	Anstadt .	
		^{US-} 3,516,408	06/01/1970	V. L. Montanti	
		^{US-} 3,667,069	06/01/1972	Blackshear et al.	
		^{US-} 3,730,186	05/1973	Edmunds, Jr. et al.	
		^{US-} 3,791,374	02/01/1974	Guarino	
	l	^{US-} 3,995,623	12/01/1976	BLAKE ET AL,	
		^{US-} 4,309,994	01/01/1982	Grunwald	
		US- 4,345,602	08/01/1982	Yoshimura et al.	
		^{US-} 4,407,271	10/01/1983	Schiff	
		^{US-} 4,423,725	01/01/1984	Baran et al.	
		^{US-} 4,459,977	07/01/1984	PIZON ET AL,	
		^{US-} 4,490,374	12/01/1984	BANDURCO ET AL,	
- I.		^{US-} 4,493,697	01/01/1985	KRAUSE ET AL,	
		^{US-} 4,536,893	08/1985	Parravicini	
		^{US-} 4,546,759	10/1985	Solar	
		^{US-} 4,554,284	11/01/1985	STRINGER ET AL,	
\/_		^{US-} 4,685,446	08/1987	Choy	
V		^{US-} 4,705,502	11/01/1987	PATEL	

		FORE	IGN PATENT DOCU	JMENTS			
Examiner Initials*			1 - 3 1 - 9	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵	
MFD		DE 43 24 637 AI	03/09/1995	Schreiber			
1		EP 0 654 283 AI	05/24/1995	Anaya F. de Lomana			
		WO 98/03213	01/29/1998	Stevens, et al.			
		WO 98/17347	04/30/1998	Tsitlik, et al.			
		WO 98/52639	11/26/1998	Hinchliffe		L	
V		EP 0 884 064 A2	12/16/1998	Forman, et al.		$ \Box $	

Examiner		Date	•
Signaturė	MFD	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/613,654	
INFORMATION DISCLOSURE	Filing Date	07/03/03	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	KEREN, ET AL.	
	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
	Attorney Docket Number	EL 05000 0444	

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f Innown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MFD		US- 4,705,507	11/01/1987	BOYLES	
		US- 4,712,551	12/01/1987	Rayhanabad	
		US- 4,714,460	12/01/1987	CALDERON	
		US- 4,723,939	02/01/1988	ANAISE	
<u>. </u>		us- 4,753,221	06/01/1988	KENSEY ET AL	
		US- 4,781,716	11/1988	Richelsoph	
		US- 4,817,586	04/1989	Wampler	
		US- 4,834,707	05/1989	Evans	<u> </u>
		US- 4:846.831	07/1989	Skillin	
		US- 4,861,330	08/1989	Voss	
		US- 4,863,461	09/1989	Jarvik	
		US- 4,888,011	12/1989	Kung et al.	
		US- 4,902,272	02/1990	Milder et al.	
	<u> </u>	us- 4,902,291	02/1990	Kolff	
		US- 4,906,229	03/1990	Wampler	
		US- 4,909,252	03/01/1990	Goldberger	606/194
		US- 4,911,163	03/01/1990	FINA	
		US- 4,919,647	04/01/1990	Nash	600/16
V		US- 4,925,377	05/1990	Inacio et al.	

		FORE	IGN PATENT DOCU			
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁰
MFD		WO 99/22784	05/14/1999	Howansky, et al.	,	
Ī		WO 99/33407	07/08/1999	Sterman		
		WO 99/51286	10/14/1999	Talpade		L
		WO 00/41612	07/20/2000	Keren, et al.		
		WO 01/083016	04/27/2001	Keren, et al.	<u> </u>	
\mathbf{V}^{-}		WO 01/41861 A1	06/2001	Levin, et al		

			· · · · · · · · · · · · · · · · · · ·
Examiner	· · · · · · · · · · · · · · · · · · ·	Date	
	!		,
Signature	MrD	Considered	· ·
1	i ,		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Со	Complete if Known		
	Application Number	10/613,654		
INFORMATION DISCLOSURE	Filing Date	07/03/03		
	First Named Inventor	KEREN, ET AL.		
STATEMENT BY APPLICANT	Art Unit			
(Use as many sheets as necessary)	Examiner Name			
hant 3 of 13	Attorney Docket Number	EL 05360 01A1		

	-		U. S. PATEN	DOCUMENTS		
Examiner Initials*	nitials* No.1		Cite No.1 Document Number Publication Date MM-DD-YYYY Number-Kind Code ^{2 (F known)}		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
MFD		US- 4,925,443	05/1990	Heilman et al.		
MED						
	ļ	US- 4,927,407	05/01/1990	DORMAN		
		^{US-} 4,927,412	05/01/1990	MENASCHE		
		^{US-} 4,938,766	07/01/1990	Jarvik, Robert K.	<u> </u>	
		^{US-} 4,950,226	08/01/1990	BARRON		
		^{US-} 4,957,477	09/01/1990	Lundback		
		^{US-} 4,964,864	10/01/1990	Summers et al.		
		^{US-} 4,976,691	12/01/1990	Sahota, Harvinder		
		US- 4,976,692	12/01/1990	ATAD		
		^{US-} 4,990,139	02/01/1991	JANG		
		^{US-} 4,995,864	02/01/1991	Bartholomew et al.		
		^{US-} 5,002,531	03/01/1991	Bonzel	604/96	
	,	^{US-} 5,002,532	03/01/1991	GAISER ET AL,	604/101	
		^{US-} 5,053,023	10/1991	Martin	604/280	
		^{US-} 5,059,178	10/01/1991	YA		
		^{US-} 5,067,960	11/01/1991	Grandjean		
1/		^{US-} 5,069,680	12/01/1991	Grandjean		
V		^{US-} 5,073,094	12/01/1991	Dorman et al.	·	
MFD		US- 5,089,019	02/01/1992	Grandjean		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Π
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	•	Or Relevant Figures Appear	T
		·				
						Г

Examiner Signature	MFD		Date Considered	·	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO		Complete if Known		
-			Application Number	10/613,654	
INIC	INFORMATION DISCLOSURE			Filing Date	07/03/03
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Uso as many sheets as necessary)		First Named Inventor	KEREN, ET AL.	
STA		PPLICANT	Art Unit		
				Examiner Name	
Chast	4	-	13	Attorney Docket Number	EL 05360 0141

		,		DOCUMENTS		
Examiner Initials* Cite No.1 Document Number Number-Kind Code ² Mr Number-Kind Code ² Of Number Nu		MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US- 5.098.370	03/01/1992	RAHAT ET AL,		
1	ļ	US- 5,098,442	03/1992	Grandjean		
	l	^{US-} 5,112,301	05/01/1992	Fenton et al.		
		^{US-} 5,112,349	05/01/1992	Summers et al.	623/3	
		^{US-} 5,119,804	06/1992	Anstadt		
		^{US-} 5,129,883	07/01/1992	BLACK		
		^{US-} 5,131,905	07/1992	Grooters		
		^{US-} 5,135,474	08/01/1992	SWAN ET AL,	•	
		^{US-} 5,158,540	10/01/1992	WIJAY ET AL,		
		^{US-} 5,163,910	11/01/1992	SCHWARTZ ET AL,		
		^{US-} 5,167,628	12/1992	Boyles		
		^{US-} 5,180,364	01/01/1993	Ginsburg, Robert		
		^{US-} 5,205,810	04/1993	Guiraudon et al.		
		^{US-} 5,226,888	07/01/1993	Arney	604/96	
		^{US-} 5,256,141	10/01/1993	GENCHEFF ET AL,		
		^{US-} 5,257,974	11/1993	Cox	604/96	
		^{US-} 5,282,784	02/01/1994	Willard	604/8	
		^{US-} 5,290,227	03/1994	Pasque		
V		^{US-} 5,308,319	5/1994	lde et al.	600/18	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Π
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	4					
	4					
	4					L
	4					L
	4					L
	4					Γ

 caminer gnature	MFD	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

FLO5360.01A1

Under the Paperwork Reduction Act of 1995, no persons are required to	respond to a collection of inform	nation unless it contains a valid OMB control number.	
Substitute for form 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	. Application Number	10/613,654	
INFORMATION DISCLOSURE	Filing Date	07/03/03	
	First Named Inventor	KEREN, ET AL.	
STATEMENT BY APPLICANT	Art Unit		
(Use as many sheets as necessary)	Examiner Name		

13

Sheet

Attorney Docket Number

Farancia a a	T 0'4-			DOCUMENTS	I Barra Calumna Linea Whore	
Examiner Initials*	No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
MFD		US- 5,308,320	05/1994	Safar et al.		
		US- 5,312,343	05/01/1994	KROG ET AL,		
		^{US-} 5,320,604	06/01/1994	WALKER ET AL,		
		^{US-} 5,326,374	07/1994	Ilbawi et al.		
		US- 5,328,470	07/01/1994	NABEL ET AL,		
		^{US-} 5,332,403	07/1994	Kolff		
		^{US-} 5,358,519	10/1994	Grandjean		
		^{US-} 5,364,337	11/1994	Guiraudon et al.		
		^{US-} 5,370,617	12/06/1994	Sahota		
		^{US-} 5,383,840	01/01/1995	Heilman et al.		
		^{US-} 5,397,307	03/01/1995	GOODIN		
		^{US-} 5,429,584	07/1995	Chiu		
		^{US-} 5,453,084	09/01/1995	Moses		
1		^{US-} 5,464,449	11/01/1995	RYAN ET AL,		
		^{US-} 5,478,331	12/26/1995	Helflin et al.		
		US- 5,484,385	01/01/1996	RISHTON		
		^{US-} 5,505,701	04/01/1996	Anaya Fernandez de Lomana	604/99	
1		US- 5,509,428	04/01/1996	Duniop	128/898	
V		^{US-} 5,536,250	07/16/1996	Klein et al.		

Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
						╀

Examiner Signature	MFD	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete ii Anonn					
Application Number	10/613,654				
Filing Date	07/03/03				
First Named Inventor	KEREN, ET AL.				
Art Unit					
Examiner Name					
Attorney Docket Number	FLO5360,01A1				

			U. S. PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Cite No.¹ Number-Kind Code² (F known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevan Figures Appear	
MFD		^{US-} 5,558,617	09/1996	Heilman et al.		
1 .	1	US- 5,599,306	02/01/1997	Klein et al.		
		US- 5,609,628	03/01/1997	KERANEN		
		^{US-} 5,613,949	03/01/1997	Miraki		
		US- 5,617,878	04/01/1997	TAHERI		
		^{US-} 5,643,171	07/01/1997	Bradshaw et al.	600/1	
		US- 5,643,215	07/01/1997	FUHRMAN ET AL,		
· [^{US-} 5,702,343	12/1997	Alferness		
	Ī	^{US-} 5,713,860	02/03/1998	Kaplan et al.		
		US- 5,720,735	02/01/1998	Dorros		
		^{US-} 5,755,779	05/01/1998	HORIGUCHI		
		່ ^{ປຣ-} 5,762,599	06/01/1998	SOHN		
		^{US-} 5,776,190	07/1998	Jarvik		
		US- 5,797,876	08/01/1998	SPEARS ET AL,		
		US- 5,90 <u>2,229</u>	05/1999	Tsitlik et al.		
		^{US-} 5,902,336	05/01/1999	MISHKIN		
		US- 5,913,852	6/1999	Magram		
V		^{US-} 5,928,132	07/01/1999	LESCHINSKY		
MFD		US- 5.935.924	08/1999	Bunting et al.	· ·	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	,	Or Relevant Figures Appear	T°

Examiner		Date	
Signature	MFD	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

5	Substitute for form 1449/PTO	,		Cor	07/03/03 entor KEREN, ET AL
				Application Number	10/613 654
1	INFORMATIO	N DIG	CLOSUDE	Filing Date	
				First Named Inventor	
	STATEMENT			Art Unit	
	(Use as many s	heets as n	ecessary)	Examiner Name	
She	et 7	of	13	Attorney Docket Number	FLO5360.01A1

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MFD		US- 5,971,910	10/1999	Tsitlik et al.	
		US- 5,984,955	11/01/1999	WISSELINK	
	Ţ.	^{US-} 6,039,721	03/21/2000	Johnson et al.	
		US- 6.077.256	06/01/2000	Mann	
		6.086.527	07/01/2000	Talpade	600/18
	<u> </u>	08-6 117 117	09/01/2000	Mauch	
		6,387,037	05/14/2002	Bolling et al.	
		US- 6,390,969	05/21/2002	Bolling et al.	
		US- 6,508,787	01/21/2003	Erbel et al.	
, , ,		US- 1,696,018	12/01/1928	Schellberg	
V		^{US-} 5,345,927	09/01/1994	Bonutti	
		US-			
		US-	<u> </u>		
		US-			
	 	US-	:		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear			
		·						
						·		

Examiner		Date	
Signature	MED	Considered	i
Q.g.,	MFD .	Considered] .

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/P	ro			Complete if Known	
0000000	10 10/10/11/1440/1	. •		Application Number	10/613,654	
INFO	ORMATIC	ON DIS	SCLOSURE	Filing Date	07/03/2003	
STA	TEMENT	BYA	PPLICANT	First Named Inventor	KEREN, et al.	
	///	6 4		Art Unit		
	(Use as many	sneets as i	necessary)	Examiner Name		
Sheet	8	of	13	Attorney Docket Number	FLO5360.01A1	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MFD		MARGULIES, et al., Intra-Arterial Atrial Natriuretic Factor (ANF) Attenuates Radiocontrast-Induced etc., Renal Pathology, unknown date, pp. 666, Abstract only	-		
		DEL GRECO, The Kidney in Congestive Heart Failure, Modern Concepts of Cardiovascular Disease, Sept. 1975, Vol 44, No. 9, pp. 47-52			
		Bischoff, W. et al.; "MODIFIED IN SITU PERFUSION OF THE KIDNEY USING BALLOON CATHETERS," Vol. 94, No. 30, pp. 1695-1697, October 21,1976. ABSTRACT ONLY.			
		Eisenberger, F. et al.; 'TRANSFEMORAL CANNULATION OF THE RENAL VESSELS. DIAGNOSTIC AND THERAPEUTIC USE IN UROLOGY," Urologe [A], Vol. 16, No. 1, pp. 1-5, January, 1977. ABSTRACT ONLY.			
		Linden, R.J. et al.; "THE NATURE OF THE ATRIAL RECEPTORS RESPONSIBLE FOR A REFLEX DECREASE IN ACTIVITY IN RENAL NERVES IN THE DOG," The Physiological Society, pp. 31-40, (1980).			
		EISENBERG, et al., Renal Failure After Major Angiography, Am J Med, Jan. 1980, Vol. 68, pp. 43-46			
		EISENBERG, et al., Renal Failure after Major Angiography Can be Avoided with Hydration, AJR, May 1981; 136:859-861			
		THOMAS, et al. Influence of Bradykinin and Papaverine on Renal etc., Renal Physiology, Basel 5:197-205 (1982)			
$\overline{\downarrow}$		D'ELIA, et al., Nephrotoxicity from angiographic Contrast Material, "A prosepctive Study, Am J Med, May 1982, Vol. 72, pp. 719-725			
MFD		Seiter, H. et al.; "MODIFIED T-CATHETER AND ITS USE FOR TRANSVENOUS HYPOTHERMIC IN SITU PERFUSION IN THE SURGICAL RESTORATION OF THE KIDNEY WITH STAGHORN CALCULI," Z. Urol Nephrol., Vol. 76, No. 6, pp. 403-406, June, 1983. ABSTRACT ONLY.			

Examiner	Van	Date	
Signature	MFD	Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

$\overline{}$	e for form 1449/PTO				Complete if Known
	0 10/ 10/11/ 1445// 10			Application Number	10/613,654
INFO	ORMATION	DIS	CLOSURE	Filing Date	07/03/2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	KEREN, et al.
	(Use as many she	ote se n	acaesand	Art Unit	
	(Use as many site	WLS 83 11	ecessary)	Examiner Name	
Sheet	9	of	13	Attorney Docket Number	FLO5360.01A1

<u> </u>	O:4=	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MFD		THOMAS, et al. Glomerrular filtration dynamics during renal vasodilation etc. Am. J. Physiol. 244:F606-F611 (1983)	
MFD		ELKAYAM, et al., Renal Hemodynaic Effects of Vasodilation with Nifedipine and Hydralazine in Patients With Heart Failure, JACC Dec 1984;Vol 4, No. 6, pp. 1261-1267	
MFD		Kehrer, G. et al.; "CONSTRUCTION AND EXPERIMENTAL APPLICATION OF A CATHETER FOR SELECTIVE ARTERIAL KIDNEY PERFUSION IN SITU," Urol. Res., Vol. 13, No. 2, pp. 85-89,(1985). ABSTRACT ONLY.	
MFD		MASON, et al., Renal Dysfunction After Arteriography, JAMA, 1985;253:1001-1004	
MFD		Walker, H.S. et al.; USE OF A BALLOON-TIPPED PERFUSION CATHETER FOR RENAL PRESERVATION DURING SUPRARENAL ABDOMINAL AORTIC OPERATIONS, J. Vasc. Surg., Vol. 2, No. 2, pp. 337-339, March, 1985. ABSTRACT ONLY.	
MFD		TALIERCIO, et al., Risks for Renal Dysfunction with Cardiac Angiography, Annals of Internal Medicine, 1986;104:501-504	
MFD		LASS, et al., Cardiovascular and Renal Hemodynamic Effects of Intravenous Infusions of the Selective DA1 Agonist etc., Circulation 1988;78:1310-1315	
MFD		VARI et al., Induction, prevention and mechanisms of contrast media-induced acute renal failure, Kidney International, 1988; 33:669-707	
MFD		PARFREY, et al., Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both, N Engl J Med 1989; 320:143-149	
MFD		SCHWAB, et al., Contrast Nephrotoxicity: A Randomized Controlled Trial of a Nonionic and an Ionic Radiographic Contrast Agent, N Engl J Med, 1989, 320:149-153	

Examiner	MFD	Date
Signature	MrD	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of Information unless it contains a valid OMB control number. Under the Panerwork Reduction Act of 1995, no nersons are required to respond to a collection of lefe

Substitu	te for form 1449/PT				Complete if Known	
000000		•		Application Number	10/613,654	
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	07/03/2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	KEREN, et al.	
				Art Unit		
	(Use as many s	sneets as i	iecessary)	Examiner Name		
Sheet	10	of	13	Attorney Docket Number	FLO5360.01A1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MFD		MARGULIES, et al., Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure, Kidney Int. 1990; Vol. 38:1101-1108	
MFD		Akaba, N. et al.; "A CYLINDER-SHAPED BALLOON CATHETER FOR THE MANAGEMENT OF DISSECTING ANEURYSMS IN ACUTE STAGE," Herz, Vol. 17, No. 6, pp. 390-393, December, 1992. ABSTRACT ONLY.	
MFD		Kobayashi, A. et al.; "EXPERIMENTAL STUDY ON THE USEFULNESS OF THE AUTOPERFUSION BALLOON CATHETER IN MAINTAINING THE BLOOD SUPPLY TO THE DISTAL ORGANS," Nippon Igaku Hoshasen Gakkai Zasshi, Vol. 52, No. 5, pp. 682-684, May	
MFD		Williams, D.M. et al.; "DESIGN AND TESTING OF A HIGH-FLO2 AUTOPERFUSION CATHETER: AN EXPERIMENTAL STUDY," J. Vasc. Interv. Radiol., Vol. 3, NO. 2, pp. 285-290, May, 1992. ABSTRACT ONLY.	
MFD		Katsumata, T. et al.; "NEWLY-DEVELOPED CATHETER FOR CARDIO-RENMAL ASSIST DURING INTRAAORTIC BALLOON COUNTERPULSATION;" Kyobu Geka, Vol. 46, No. 9, pp. 767-770, August, 1993. ABSTRACT ONLY.	
MFD		PATEL, et al. Intravenous Fenoldopam Infusion in Severe Heart Failure, Cardiovasc Drugs Ther 1993;7:97-101	
MFD		SHUSTERMAN, et al. Fenoldopam, But Not Nitroprusside, Improves Renal Function etc. Am J of Medicine, 95:161-168 (1993)	
MFD		Novick, A.C.; "ATHEROSCLEROTIC ISCHEMIC NEPHROPATHY. EPIDEMIOLOGY AND CLINICAL CONSIDERATIONS," Urol. Clin. North Am, Vol. 21, No. 2, pp. 195-200, May, 1994. ABSTRACT ONLY	·
MFD		SOLOMON, et al., Effects of Saline, Mannitol, and Furosemide on Accute Decreases in Renal Function etc., N Engl J Med 1994; Vol 331 No. 21 pp. 1416-1420	
MFD		STRICK, et al., Direct measurement of renal medullary blood flow in the dog, Am J. Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R253-R2259, 1994	

Examiner	MFD	 Date	
Signature	Mr D	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	te for form 1449/PTO				Complete if Known
				Application Number	10/613,654
INFO	ORMATION	DIS	CLOSURE	Filing Date	07/03/2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	KEREN, et al.
	(Use as many she	ata as s	oooccaad	Art Unit	
	(Ose as many sne		iecessary)	Examiner Name	
Sheet	11	of	13	Attorney Docket Number	FLO5360.01A1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MFD		Levin, Howard R. et al.; "REVERSAL OF CHRONIC VENTRICULAR DILATION IN PATIENTS WITH END-STAGE CARDIOMYOPATHY BY PROLONGED MECHANICAL UNLOADING," Vol. 91, No. 11, pp. 2717-2718, June 1, 1995.	
MFD		Masaki, Z. et al.:"IN-SITU PERFUSION BY RETROGRADE CANNULLATION OF A TUMOR ARTERY FOR NEPHRON-SPARING SURGERY," Int. J. Urol, Vol. 2, No. 3, pp. 161-165, July, 1995. ABSTRACT ONLY.	
MFD		RUDNICK, et al., Nephrotoxicity of ionic and noionic contrast media in 1196 patients: A randomized trial, Kidney International, 1995;47:254-261	
MFD		Cohn, Jay N.; "THE MANAGEMENT OF CHRONIC HEART FAILURE," The New England Journal of Medicine, pp. 490-498, August 15, 1996.	
MFD		ELKAYAM, et al., Renal Vasodilatory Effect of Endothelial Stimulation in Patients with Chronic Congestive Heart Failure, J Am Coll Cardiol 1996;28:176-182	
MFD		Iannone, L.A. et al - "EFFECT OF PRIMARY BALLOON EXPANDABLE RENAL ARTERY STENTS ON LONG-TERM PATENCY RENAL FUNCTION AND BLOOD PRESSURE IN HYPERTENSIVE AND RENAL INSUFFICIENT PATIENTS WITH RENAL ARTERY STENOSIS," Cathet. Cardiovase.	
MFD		Greco, B.A. et al.; "ATHEROSCLEROTIC ISCHEMIC RENAL DISEASE," Am J. Kidney Dis., Vol. 29, No. 2, pp. 167-187, Feb., 1997. ABSTRACT ONLY.	,
MFD		MCCARTHY, Animal Models in Medical Device Development and Qualification, Charles River laboratories, Vol 10(2) 1997	
MFD		MCCULLOUGH, et al., Acute Renal Failure after Coronary Intervention: Incencence, Risk Factors, and Relationship to Mortality, Am J Med. 1997;103:368-375	
MFD		White, C.J. et al.; "RENAL ARTERY STENT PLACEMENT: UTILITY IN LESIONS DIFFICULT TO TREAT WITH BALLOON ANGIOPLASTY," J. Am. Coll. Cardiol., Vol. 30, No. 6, pp. 1445-1450, November 15,1997. ABSTRACT ONLY	

Examiner	MFD	Date
Signature		Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).
2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
as collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			 	Complete if Known		
, 02550.0.				Application Number	10/613,654	
INFO	ORMATION	DIS	CLOSURE	Filing Date	07/03/2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	KEREN, et al.	
	(llee ee meny she			Art Unit		
(Use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	12	of	13	Attorney Docket Number	FLO5360.01A1	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MFD	Canaud, B. et al.; "TEMPORARY VASCULAR ACCESS FOR EXTRACORPOREAL RENAL REPLACEMENT THERAPIES IN ACUTE RENAL FAILURE PATIENTS," Kidney Int. Suppl., Vol. 66, pp. S142-S150, May, 1998. ABSTRACT ONLY			
MFD		DRESCHER, et al., Prevention of Contrast Medium-Induced Renal Vasospasm by Phosphodiesterase Inhibition, Invest Radiol 1998;33:858-862		
MFD	Garwood, Susan et al.; "RENAL PRESERVATION STRATEGIES FOR HIGH RISK PATIENTS," University of Chico School of Medicine, Cover Page, Table of Contents Page, pp. 1-19, (1998).			
MFD		Jacobs, M.J. et al.; "REDUCED RENAL FAILURE FOLLOWING THORACOABDOMINAL AORTIC ANEURYSM REPAIR BY SELECTIVE PERFUSION," Eur. J. Cardiothorac. Surg., Vol. 14, No. 2, pp. 201-5, August, 1998. ABSTRACT ONLY		
MFD		Mathis, J.M. et al., "USE OF A GUIDE CATHETER AS A TEMPORARY STENT DURING MICROCATHETER INTERVENTION," AJNR Am. J. Neuroradiol, Vol. 19, No. 5, pp. 932-933, May, 1998. ABSTRACT ONLY.		
MFD		Middleton, J.P.; "ISCREMIC DISEASE OF THE KIDNEY: HOW AND WHY TO CONSIDER REVASCULARIZATION," J. Nephrol., Vol. 11, No. 3, pp. 123-136, May-June, 1998. ABSTRACT ONLY.		
MFD		Postma, C.T. et al.; "TREATMENT OF RENAL ARTERY STENOSIS WITH INTRA-ARTERIAL STENTS," Ned Tijdschr Geneeskd, Vol. 142, No. 39, pp. 2132-7, September 26,1998. ABSTRACT ONLY		
MFD		BAKRIS, et al., Renal hemodynamics in radiocontrast medium-induced renal dysfunction etc. Kidney International, Vol. 56 pp. 206-210 (1999)		
MFD		Bergey, E.A. et al.; "TRANSHEPATIC INSERTION OF VASCULAR DIALYSIS CATHETERS IN CHILDREN: A SAFE, LIFE-PROLONGING PROCEDURE," Pediatr. Radiol., Vol. 29, No. 1, pp. 42-50, Jan. 1999. ABSTRACT ONLY		
MFD		Fox, S. I.; "MECHANISMS OF CONTRACTION," Human Physiology, Fourth Edition, pp. 300-323.		

Examiner			Date	
Signature	MFD	•	. Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	der the Paperwork R		act of 1995, no persons ar		PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number. Complete if Known
Substitute for form 1448/F 10				Application Number	10/613,654
INFORMATION DISCLOSURE				Filing Date	07/03/2003
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	KEREN, et al.
				Art Unit	
	(Use as many s	heets as i	necessary)	Examiner Name	
Sheet	13	of	13	Attorney Docket Number	FLO5360.01A1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD		HEYMAN, et al., Pathophysiology of Radiocontrast Nephropathy, A Role for Medullary Hypoxia, Invest Radiol, 1999;34:685-691	
MFD		KIM et al. Fluoroscopic Landmarks for Optimal Visualization of the Proximal Renal Arteries, JVIR, 10:37-39 (1999)	
MFD		STEVENS, et al., A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, J Am Coll Cardiol, 1999;33:403-411	

_			
Examiner	/Matthew DeSanto/	Date Considered	01/05/2007
Signature	,,	Constacted	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.